$16.42
2.63% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Rigel Pharmaceuticals, Inc. Stock price

$16.42
+3.21 24.30% 1M
+1.52 10.20% 6M
+1.92 13.24% YTD
+5.32 47.93% 1Y
-21.38 56.56% 3Y
-1.88 10.27% 5Y
-3.58 17.90% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.42 2.63%
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Key metrics

Market capitalization $281.52m
Enterprise Value $292.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.25
P/S ratio (TTM) P/S ratio 2.16
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2.89%
Revenue (TTM) Revenue $130.30m
EBIT (operating result TTM) EBIT $-9.02m
Free Cash Flow (TTM) Free Cash Flow $-12.31m
Cash position $49.10m
EPS (TTM) EPS $-0.81
P/E forward negative
P/S forward 1.82
EV/Sales forward 1.89
Short interest 3.40%
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
130 130
3% 3%
100%
- Direct Costs 9.89 9.89
275% 275%
8%
120 120
3% 3%
92%
- Selling and Administrative Expenses 107 107
4% 4%
82%
- Research and Development Expense 21 21
53% 53%
16%
-7.41 -7.41
77% 77%
-6%
- Depreciation and Amortization 1.61 1.61
36% 36%
1%
EBIT (Operating Income) EBIT -9.02 -9.02
73% 73%
-7%
Net Profit -14 -14
62% 62%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
16 days ago
SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Cantor Global Healthcare Conference on Thursday, September 19, at 9:10 am ET in New York, NY.
Neutral
PRNewsWire
23 days ago
First trial in Rigel's multi-year strategic development alliance with MD Anderson Phase 1b/2 trial of decitabine and venetoclax in combination with Rigel's targeted mIDH1 inhibitor REZLIDHIA for patients with mIDH1 AML SOUTH SAN FRANCISCO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders ...
Neutral
PRNewsWire
25 days ago
Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea  and Taiwan Rigel will receive an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments Rigel to receive product transfer price payments in the mid-twenty ...
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 147
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today